Allogene Therapeutics Inc
NASDAQ:ALLO

Watchlist Manager
Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc
NASDAQ:ALLO
Watchlist
Price: 2.54 USD -6.62% Market Closed
Market Cap: 531.1m USD
Have any thoughts about
Allogene Therapeutics Inc?
Write Note

Allogene Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allogene Therapeutics Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Allogene Therapeutics Inc
NASDAQ:ALLO
Cash from Financing Activities
$111.1m
CAGR 3-Years
65%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1B
CAGR 3-Years
8%
CAGR 5-Years
-49%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Allogene Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
111.1m USD

Based on the financial report for Sep 30, 2024, Allogene Therapeutics Inc's Cash from Financing Activities amounts to 111.1m USD.

What is Allogene Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-20%

Over the last year, the Cash from Financing Activities growth was 16%. The average annual Cash from Financing Activities growth rates for Allogene Therapeutics Inc have been 65% over the past three years , -20% over the past five years .

Back to Top